15/11/2011

The Actuarial Profession making financial sense of the future

Survival extension from advances in cancer treatment Helen Chung and Nicola Oliver, Swiss Re



Overview

- Background
 - · Determinants of mortality
 - Cancer mortality
- · Recent advances in cancer treatment
- · From the laboratory to clinical practice
 - Pharmaceutical development pipeline
 - Regulation
 - NICE guidance
- · Evidence for survival extension
 - Clinical trials

© 2010 The Actuarial Profession • www.actuaries.org.uk

- Models over life-time horizons
- Impedance to inference
 pitfollo, covorto and convent
 - pitfalls, caveats and conundrums
- Context of longevity research
- Discussion and questions


Thomas McKeown

© 2010 The Actuarial Profession • www.actuaries.org.uk




2

- Physician and Demographic Historian put forward a body of research between the 1950's and the 1980's 'The McKeown Thesis'
- Principally concerned with the role of medicine and population change
- Proposed that 'population growth was due primarily to a decline in mortality from infectious disease driven by improved economic conditions...other variables such as medical interventions, sanitary reforms and the decline in infectious organisms played a marginal role...'





Historical markers in public health



The 20 most common causes of death from cancer, UK, 2008


Lung cancer, five-year relative survival rate, England and Wales, 1971-2006 (age-standardised)





Colon cancer, five-year relative survival rate, England and Wales, 1971-2006 (age-standardised)

Breast cancer, five-year relative survival rate, England and Wales, 1971-2006 (age-standardised)



What about recent medical advances?

- Targeted therapies a major advance in last 20 to 30 years
 - monoclonal antibodies
 - small molecules
- Chemotherapy

© 2010 The Actuarial Profession • www.actuaries.org.uk

- · classes, generations
- · sequences, combinations
- · Radiotherapy, surgical techniques, best supportive care
- · Important to remember that advances occur at all stages of the life course, not just after diagnosis
 - health promotion, disease prevention, screening, diagnostics, surveillance techniques

Overview of the clinical trial process and regulatory assessment

Study subject	3 – 5 years Laboratory	20-80	2 years 100 - 300	3 years 1′000 -	2 years —	open open,
subject a			100 - 300	1′000 -	-	open
:	and animal studies	healthy volunteers	patient volunteers	3'000 patient volunteers		according to indication
aim i	Assess safety & biol. activity IND ¹ Submissio	Determine safety & max. dose	Evaluate effective dose, side effects	Verify efficacy, monitor long term	Review process	Post marketing safety monitoring

NICE (National Institute for Health and Clinical Excellence)

- Independent organization responsible for providing national guidance on promoting good health and preventing and treating ill health
- Produces several types of guidance
 Clinical Guidelines, Public Health, Tech Appraisals
- Technology appraisals include rigorous systematic reviews of clinical evidence, economic evaluation, multiple stakeholder opinions and submissions, deliberation of a multidisciplinary committee in public, consultation and right of appeal
- Have carried mandatory funding direction
- Only certain topics are prioritised for appraisal, in accordance with clear criteria

Measures of survival in clinical trials

- Progression-free survival
- Overall survival

© 2010 The Actuarial Profession • www.actuaries.org.uk

- · Median survival
- · Hazard ratios/Relative risks
- Other outcomes
 - Response rates
 - Response definitions
 - Improvement in operability
 - · Duration of response / time to relapse
- Adverse effects

© 2010 The Actuarial Profession • www.actuaries.org.uk

11


Estimating life years gained

- · Cost effectiveness models
 - Cost per QALY gained = ICER
 - QALY = quality-adjusted life year
- Time horizon long enough to capture differences between treatment arms (life time for chronic illness)
- Extrapolation beyond clinical trial data
- Parametric curve fitting and its perils
- · Means and medians
- · Area under the curve

© 2010 The Actuarial Profession • www.actuaries.org.uk

- · LYG, QALYs and ICERs
- Sensitivity and scenario analyses results can be pretty variable






Scope and methods of this exercise

- NICE Technology Appraisals with positive recommendations between 2005 to 2010
- Focus on lung, breast and colorectal cancers, on grounds of being most common causes of cancer death, but note that there are more life years lost per person due to some other cancers
- Limited to clinical trial comparisons and base case assumptions – these are often not the most generalisable and plausible assumptions for current UK setting
 - Clinical trial evidence usually ITT from regulatory trial
 - Modeled life years gained manufacturer's base case (STA); Assessment Group base case (MTA)


Lung cancer treatments NB: heterogeneous populations

© 2010 The Actuarial Profession • www.actuaries.org.uk

parator		HR (95% CI)
		. ,
supportive care	—	0.70 (0.58, 0.85)
citabine/cisplatin	—	0.84 (0.74, 0.96)
supportive care	→	0.70 (0.56, 0.88)
supportive care	•	0.61 (0.43, 0.87)
axel/carboplatin		0.91 (0.76, 1.10)
	citabine/cisplatin supportive care supportive care taxel/carboplatin	citabine/cisplatin




Indicated/recommended populations as a proportion of total incident lung cancer cases




Colorectal cancer treatments *NB: heterogeneous populations*

Intervention	Comparator		HR (95% CI)
Cetuximab+FOLFIRI [KRAS Wild-type subgroup]	FOLFIRI		0.84 (0.64, 1.11)
Irinotecan+5-FU/FA[1st line]	5-FU/FA		0.84 (0.76, 0.93)
Oxaliplatin+5-FU/FA[1st line]	5-FU/FA		0.93 (0.83, 1.03)
Raltitrexed[1st line]	5-FU/LV	+	1.10 (0.97, 1.25)
Capecitabine	5-FU/LV		0.88 (0.74, 1.05)
Oxaliplatin+5-FU/LV [Stage III Colon subgroup]	5-FU/LV		0.86 (0.68, 1.08)

Colorectal cancer treatments







Indicated/recommended populations as a proportion of total incident colorectal cancer cases

Breast cancer treatments *NB: heterogeneous populations*

Intervention	Comparator		HR (95% CI)
Frastuzumab	Observation	→	0.66 (0.57, 0.77)
Oocetaxel[TAC]	FAC	→	0.70 (0.53, 0.93)
Anastrazole[HR +ve]	Tamoxifen	-+	0.97 (0.83, 1.14)
Exemestane	Tamoxifen		0.83 (0.67, 1.02)
_etrozole	Tamoxifen		0.86 (0.70, 1.06)
Gemcitabine[GT]	Paclitaxel(T)		0.82 (0.67, 1.00)
	.5	1	1.5



Indicated/recommended populations as a proportion of total incident breast cancer cases



Slim pickings, or the hint of distant promise?

- Innovation, much like policy change, tends to happen more often by 'creeping incrementalism', rather than 'step change'
- So, whilst the impact of an individual new treatment might look modest, it could be the first step towards much greater change in the future
- Cumulative effects on survival of extended indications over time:
 - e.g. rituximab for follicular NHL first marketing authorisation at stage III/IV after prior treatments

Inference considerations and conundrums

Comparators


© 2010 The Actuarial Profession • www.actuaries.org.uk

- Intervention: licensed regimen and dosing vs clinical practice
- · Clinical trial design: endpoint timing, cross over
- Subgroups
- Modelled life years gained
 - Manufacturer vs Assessment Group
 - Base case vs sensitivity/scenario analysis
 - Discounting of health benefits
- Generalisability

© 2010 The Actuarial Profession • www.actuaries.org.uk

Implementation & uptake: licensed indication vs NICE recommendation

25



A window into the future:

Considerations when building a forward-looking, disease-centred approach to assessing future longevity, Swiss Re, 2011

Questions or comments?

© 2010 The Actuarial Profession • www.actuaries.org.uk

Expressions of individual views by members of The Actuarial Profession and its staff are encouraged. The views expressed in this presentation are those of the presenter.